“…In a previous study, obacunone attenuated ulcerative colitis symptoms in mice by modulating the gut microbiota, disrupting the TLR4/NF-κB signaling cascades, and restoring intestinal epithelial barrier integrity ( Luo et al, 2020 ). Ulcerative colitis increases CGS prevalence by influencing bile acids and gall bladder emptying ( Mark-Christensen et al, 2017 ; Malik and Aurelio, 2023 ), where bile stasis leads to bile dehydration, increasing cholesterol concentration ( Damião et al, 1997 ), and stone precipitation. Furthermore, obacunone prevents obesity and hyperglycemia, two independent risk factors for CGS ( Lammert et al, 2016 ), by activating TGR5 and inhibiting PPARγ transcriptional activity ( Horiba et al, 2015 ), which are related to bile metabolism ( Chávez-Talavera et al, 2017 ; Jia et al, 2018 ; Sorrentino et al, 2020 ; Castellanos-Jankiewicz et al, 2021 ) and CGS formation ( Dong et al, 2011 ; Wang et al, 2018 ; Han et al, 2019 ).…”